<DOC>
	<DOCNO>NCT01470703</DOCNO>
	<brief_summary>This international multicenter , randomize , open trial evaluate impact Extracorporeal Membrane Oxygenation ( ECMO ) , institute early diagnosis acute respiratory distress syndrome ( ARDS ) evolve favorably 3-6 hour optimal ventilatory management maximum medical treatment , morbidity mortality associate disease .</brief_summary>
	<brief_title>Extracorporeal Membrane Oxygenation Severe Acute Respiratory Distress Syndrome</brief_title>
	<detailed_description>Background : The acute respiratory distress syndrome ( ARDS ) generally severe pulmonary disease , whose associated mortality remain high . The severe form ARDS , hypoxemia induce lung involvement profound , even dismal prognosis , mortality rate exceed 60 % , despite resort exceptional adjunctive therapy , like NO inhalation , prone positioning patient , almitrine infusion high frequency oscillation ( HFO ) -type ventilation . In situation , certain team propose establish extracorporeal circuit , combine centrifuge pump oxygenator membrane , assure total pulmonary assistance ( oxygenation CO2 removal blood ) , Extra-Corporeal Membrane Oxygenation ( ECMO ) . The aim ECMO minimize trauma induce mechanical ventilation allow lung rest . Unfortunately , trial evaluate ECMO indication past decade failure interval onset disease installation assistance , poor oxygenation CO2-removal capacity device use , high rate complication link apparatus ( massive hemorrhage result intense anticoagulation poor 'biocompatibility ' circuit ) . However , past year , decisive progress make conception construction ECMO circuit , render 'biocompatible ' , well perform resistant . Finally , result therapeutic trial ( CESAR , UK ) use late generation ECMO promising . Thus , investigator strong clinical pathophysiological rationale evaluate , clinical trial sufficient statistical power , impact early ECMO installation severe form ARDS . This project integrate network ( REVA Network Mechanical Ventilation ) program . Study hypothesis : ECMO , institute early diagnosis ARDS evolve favorably 3-6 hour optimal ventilatory management maximum medical treatment , would lower morbidity mortality associate disease . Methods : A multicenter , randomize , open trial . Twenty-three center participate project conduct within REVA network . Experimental treatment arm : ECMO initiate rapidly possible venovenous access . The material use consist pre-heparinized cannulae tubing , centrifuge pump heparinized membrane oxygenator ( Quadrox® , Jostra® , Maquet® ) . To minimize trauma induced mechanical ventilation , follow ventilator setting use : volume-assist control mode , FiO2 30-60 % , PEEP ≥ 10 cm H2O , VT lower obtain plateau pressure &lt; 25 cm H2O , respiration rate ( RR ) 10-30/minute APRV mode high pressure level &lt; 25 cm H2O low pressure level ≥10 cm H2O . Control arm treatment : Standard management ARDS , accord modality apply 'maximal pulmonary recruitment ' group EXPRESS trial ( 1 ) : assist-controlled ventilatory mode , VT set 6 ml/kg ideal body weight PEEP set exceed plateau pressure 28-30 cm H2O . In case refractory hypoxemia , usual adjunctive therapeutic use : NO , prone position , HFO ventilation , almitrine infusion . A cross-over option ECMO possible case refractory hypoxemia define blood arterial saturation SaO2 &lt; 80 % &gt; 6 hour , despite mandatory use recruitment maneuver , inhale NO/prostacyclin technically possible test prone position , patient irreversible multiple organ failure physician charge patient believe could actually change outcome . Objective judgement criterion : The primary endpoint achieve , ECMO , significantly low mortality day ( D ) 60 ( D1 day randomization ) . Secondary objective show : benefit term low ICU hospital mortality rate D30 D90 ; low pneumothorax frequency ; shorten duration mechanical ventilation ; le need hemodynamic support catecholamine ; short ICU hospital stay ; day , inclusion D60 , without mechanical ventilation , without organ failure without hemodynamic support . Statistical analysis : The high mortality rate severe ARDS ( ≥ 60 % ) justify combine effort reach rapid conclusion thus resort sequential analytical plan , stop rule base triangular test . Thus , 80 % power 5 % α-risk hypothesis ECMO achieve 20 % absolute mortality reduction , characteristic study , calculate triangle test , follow : maximum 331 subject include 90 % probability stop study 220 subject include .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>Inclusion criterion : 1 . ARDS define accord follow criterion ( 9 ) : Intubation mechanical ventilation ≤ 6 day Bilateral radiological pulmonary infiltrates consistent edema PaO2/FiO2 ratio &lt; 200 mm Hg Absence clinical evidence elevate left atrial pressure and/or pulmonary arterial occlusion pressure ≤ 18 mm Hg 2 . One 3 follow criterion disease severity : i. PaO2/FiO2 &lt; 50 mm Hg FiO2 ≥ 80 % &gt; 3 hour , despite optimization mechanical ventilation ( Vt set 6 ml/kg trial PEEP ≥ 10 cm H2O ) despite possible recourse usual adjunctive therapy ( NO , recruitment maneuver , prone position , HFO ventilation , almitrine infusion ) OR ii . PaO2/FiO2 &lt; 80 mm Hg FiO2 ≥ 80 % &gt; 6 hour , despite optimization mechanical ventilation ( Vt set 6 ml/kg trial PEEP ≥ 10 cm H2O ) despite possible recourse usual adjunctive therapy ( NO , recruitment maneuver , prone position , HFO ventilation , almitrine infusion ) OR iii . pH &lt; 7.25 &gt; 6 hour ( respiratory rate increase 35/min ) result MV setting adjust keep plat ≤ 32 cm H2O ( first , tidal volume reduction step 1 mL/kg 4 mL/kg PEEP reduction minimum 8 cm H2O . 3 . Obtain informed consent close relative surrogate . Should person absent , patient randomize accord specification emergency consent patient ask give his/her consent continuation trial his/her condition allow . Exclusion criterion : 1 . Intubation mechanical ventilation ≥ 7 day 2 . Age &lt; 18 year 3 . Pregnancy 4 . Weight &gt; 1 kg/cm BMI &gt; 45 kg/m² 5 . Chronic respiratory insufficiency treat oxygen therapy long duration and/or longterm respiratory assistance 6 . Cardiac failure require venoarterial ECMO 7 . Previous history heparininduced thrombopenia 8 . Malignancy fatal prognosis within 5 year 9 . Patient moribund day randomization SAPS II &gt; 90 10 . Non druginduced coma follow cardiac arrest 11 . Irreversible neurological pathology , example , flat EEG trace cerebral herniation… 12 . Decision limit therapeutic intervention 13 . ECMO cannula access femoral vein jugular vein impossible . 14 . CardioHelp device immediately available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Respiratory Distress Syndrome ,</keyword>
	<keyword>ECMO , Extracorporeal Membrane Oxygenation</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Positive-Pressure ventilation</keyword>
	<keyword>Survival Rate</keyword>
</DOC>